Back to Treatments

Treatment

Ivosidenib (IDH1 Inhibitor)

1
Conditions
20
Trials
300
Participants
45%
Average Safety

Condition Evidence

Gallbladder and biliary tract cancer

20 trials · 300 participants

40% effectiveness · 45% safety
Ivosidenib (IDH1 Inhibitor) | DFDA